Home / Market News / $LIVN
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

LivaNova Announces Publication of 36-Month CORE-VNS Study Results

Oct 23, 2026, 5:04 PM UTC · Primary ticker $LIVN

LivaNova announced the publication of long-term results from its CORE-VNS study, demonstrating significant and sustained effectiveness of its VNS Therapy for drug-resistant epilepsy. This positive clinical data could bolster market confidence in the therapy's long-term value and potentially drive increased adoption.

LivaNova disclosed the publication of 36-month results from its CORE-VNS study, highlighting a 76% median reduction in seizure frequency for patients with drug-resistant epilepsy. This is significant because it provides strong, long-term clinical evidence for the effectiveness of their VNS Therapy, addressing a critical need for patients who don't respond to medication. The positive data, including reduced healthcare utilization, could lead to increased physician adoption and broader insurance coverage, benefiting LivaNova directly. In the short term, this news could generate positive sentiment and potentially a modest stock price increase for LIVN, while long-term implications include sustained revenue growth and market share expansion in the epilepsy treatment space. The key opportunity for traders is the potential for increased sales and market penetration for LivaNova's VNS Therapy.

$LIVN positive Positive clinical trial results
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.